Jan 11, 2017 13:03 pm UTC| Business
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating Antibiotic Incentives Now (GAIN) Act,...
Jan 11, 2017 13:03 pm UTC| Business
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating Antibiotic Incentives Now (GAIN) Act,...
Jan 11, 2017 13:03 pm UTC| Business
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating Antibiotic Incentives Now (GAIN) Act,...
Jan 11, 2017 13:03 pm UTC| Business
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating Antibiotic Incentives Now (GAIN) Act,...
Jan 11, 2017 13:02 pm UTC| Business
SAN DIEGO, Jan. 11, 2017 -- Bionano Genomics, the leader in physical genome mapping, today announced 36 posters and workshops demonstrating how using next-generation mapping (NGM) to reveal true genome structure...
Jan 11, 2017 13:02 pm UTC| Business
SAN DIEGO, Jan. 11, 2017 -- Bionano Genomics, the leader in physical genome mapping, today announced 36 posters and workshops demonstrating how using next-generation mapping (NGM) to reveal true genome structure...
Jan 11, 2017 13:02 pm UTC| Business
SAN DIEGO, Jan. 11, 2017 -- Bionano Genomics, the leader in physical genome mapping, today announced 36 posters and workshops demonstrating how using next-generation mapping (NGM) to reveal true genome structure...